Effect of beclomethasone dipropionate on bone mineral content assessed by X-ray densitometry in asthmatic children: a longitudinal evaluation

There is little information on bone turnover in asthmatic children taking long-term treatment with inhaled steroids (ICS). The aim of this longitudinal study was to determine the effects of inhaled beclomethasone dipropionate (BDP) on bone mineral density (BMD), in asthmatic children treated over a period of six months. BMD and growth were studied in two age- and sex-matched groups of asthmatic children. These comprised: 14 asthmatic children (Group 1) who had taken BDP in a dosage of 300-400 micrograms daily through a 145 ml spacer device for at least 6 months (mean age 9.1 yrs); and a control group of 16 age- and sex-matched asthmatic patients (Group 2) not treated with ICS (mean age 9.5 yrs). Mean duration of asthma was 5.7 yrs in Group 1 and 5.5 yrs in Group 2. Vertebral BMD (L2-L4) was measured by dual energy X-ray absorptiometry (DEXA) at the beginning (baseline) of the study and 6 months later. There were no significant differences in the baseline bone mass (mean +/- SEM) between the two groups (0.63 +/- 0.03 and 0.64 +/- 0.02 g.cm-2 in Group 1 and 2, respectively). During the observation period, bone density increased, by 4% (95% confidence interval (95% CI) 2-6) in the control group and by 2.3% (95% CI 0.4-4.2) in the group under BDP treatment, showing no significant influence of the treatment. No difference was found in height velocity evaluated before starting BDP and after 6 months of therapy.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				H. W. Kelly, M. L. Van Natta, R. A. Covar, J. Tonascia, R. P. Green, R. C. Strunk, and for the CAMP Research Group Effect of Long-term Corticosteroid Use on Bone Mineral Density in Children: A Prospective Longitudinal Assessment in the Childhood Asthma Management Program (CAMP) Study Pediatrics, July 1, 2008; 122(1): e53 - e61. [Abstract] [Full Text] [PDF]

				M.J. Visser, E. van der Veer, D.S. Postma, L.R. Arends, T.W. de Vries, P.L.P. Brand, and E.J. Duiverman Side-effects of fluticasone in asthmatic children: no effects after dose reduction Eur. Respir. J., September 1, 2004; 24(3): 420 - 425. [Abstract] [Full Text] [PDF]

				P. K. Sharma, S. Malhotra, P. Pandhi, and N. Kumar Effect of Inhaled Steroids on Bone Mineral Density: A Meta-Analysis J. Clin. Pharmacol., February 1, 2003; 43(2): 193 - 197. [Abstract] [Full Text] [PDF]

				A E Tattersfield, G I Town, O Johnell, C Picado, M Aubier, P Braillon, and R Karlström Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years Thorax, April 1, 2001; 56(4): 272 - 278. [Abstract] [Full Text]

				M. F. Goldstein, J. J. Fallon Jr, and R. Harning Chronic Glucocorticoid Therapy-Induced Osteoporosis in Patients With Obstructive Lung Disease* Chest, December 1, 1999; 116(6): 1733 - 1749. [Abstract] [Full Text] [PDF]

				The use of inhaled corticosteroids in childhood asthma DTB, October 1, 1999; 37(10): 73 - 77. [Abstract] [Full Text] [PDF]

				B. J. Lipworth Systemic Adverse Effects of Inhaled Corticosteroid Therapy: A Systematic Review and Meta-analysis Arch Intern Med, May 10, 1999; 159(9): 941 - 955. [Abstract] [Full Text] [PDF]

				P. J. BARNES, S. PEDERSEN, and W. W. BUSSE Efficacy and Safety of Inhaled Corticosteroids . New Developments Am. J. Respir. Crit. Care Med., March 1, 1998; 157(3): S1 - 53. [Full Text] [PDF]

				L. AGERTOFT and S. PEDERSEN Bone Mineral Density in Children with Asthma Receiving Long-term Treatment with Inhaled Budesonide Am. J. Respir. Crit. Care Med., January 1, 1997; 157(1): 178 - 183. [Abstract] [Full Text]